Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Varying concentrations of alcohol do not alter pharmacokinetics of amphetamine

31 Aug 2017

Alcohol concentrations of between 4 and 40 percent appear to have no significant effect on the pharmacokinetic profile of the psychostimulant amphetamine, a study has found.

The phase I single-dose, open-label study included 32 healthy adults. Participants were randomized to receive amphetamine extended-release orally disintegrating tablet (AMP XR-ODT; 18.8 mg) in one of four sequences: following 240 mL of deionized water or 4, 20 or 40 percent ethanol. Blood samples were collected, and the pharmacokinetic profiles of d- and l-AMP were compared across treatment groups.

No change was seen in the extent of absorption for d- or l-AMP with alcohol coingestion. Moreover, there was no dose-dumping of the extended-release portion of the drug formulation.

The 90 percent CIs for the geometric mean ratios for Cmax (peak serum concentration the drug achieves in a specified test area of the body) and systemic exposure (area under the curve [AUC0]–5, AUClast and AUC0–∞) were in the range of 80 to 125 percent.

Adverse events were mild to moderate in severity, consistent with the known adverse event profile for AMP XR-ODT or alcohol.

The present data are relevant to clinicians who have concerns about alcohol use and/or abuse when treating attention deficit hyperactivity disorder (ADHD), researchers said.

Characterized by inattention, impulsivity and hyperactivity, ADHD can lead to alcohol and other drug (AOD)-related problems. In previous studies, it was shown that the mental disorder contributes to the development of AOD use disorders. The potential role of ADHD in the development of AOD use problems is said to have important implications for prevention and treatment of such problems. [Alcohol Res Health 2002;26:122-129]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.